SGLT-2抑制剂对心血管风险的作用及机制研究进展
首发时间:2018-03-29
摘要:钠-葡萄糖协同转运蛋白 2(SGLT-2)抑制剂是一类降糖新药,其通过作用于肾小管上皮的SGLT-2,抑制Na+和葡萄糖的重吸收,发挥降糖作用。在最近发表的系列临床研究中,SGLT-2抑制剂显示出显著的心血管保护作用。这一作用的具体机制还不清楚。本文就SGLT-2抑制剂对心血管系统的作用及其机制进行综述,以促进这类药物的合理应用。
关键词: 1. 2型糖尿病 2. 心血管风险 3. SGLT-2抑制剂
For information in English, please click here
Research progress on the effects and mechanisms of SGLT-2 inhibitors on cardiovascular risk
Abstract:Sodium-glucose transporter 2(SGLT-2) inhibitor are a novel class of hypoglycemic drugs that reduce hyperglycemia by blocking renal glucose reabsorption via SGLT-2 on epithelial cells of renal tubule, thereby reducing blood glucose. In a series of recently published clinical studies, SGLT-2 inhibitors showed significant cardiovascular protective effects, but the underlying mechanism is still unclear. This article reviews the evidence of cardiovascular effects of SGLT-2 inhibitors and studies on its mechanism, in order to promote proper application of this kind of medicine.
Keywords: Diabetes mellitus, type 2 cardiovascular risk Sodium-glucose co-transporter 2 (SGLT-2) inhibitors
引用
No.****
动态公开评议
共计0人参与
勘误表
SGLT-2抑制剂对心血管风险的作用及机制研究进展
评论
全部评论0/1000